FBT
First Trust NYSE Arca Biotechnology Index Fund
First Trust NYSE Arca Biotechnology Index Fund seeks investment results that correspond to the price and yield of an equity index called the Amex Biotechnology Index.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 2.8 B
ASSETS UNDER MGMT
56 bp
EXPENSES
Fund Basics
| Inception date | Jun 19, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| CORCEPT THERAPEUTICS INC | 4.2 % |
| REGENERON PHARMACEUTICALS | 3.9 % |
| NEOGENOMICS INC | 3.7 % |
| HALOZYME THERAPEUTICS INC | 3.7 % |
| ILLUMINA INC | 3.7 % |
| AMGEN INC | 3.6 % |
| BEIGENE LTD. SPONSORED ADR | 3.6 % |
| BRUKER CORP | 3.5 % |
| INCYTE CORP | 3.5 % |
| BIOGEN IDEC INC | 3.5 % |
Constituent Breakdown
| Number of holdings | 31 |
| Herfindahl-Hirschman Index | 333 |
| Wgt avg mkt cap (mns) | $33,364 |
| Large cap (>$10bn) | 66.6% |
| Mid cap ($2-10bn) | 23.8% |
| Small cap (<$2bn) | 9.5% |
| Developed mkts. | 96.3% |
| Emerging mkts. | 3.6% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 83.1 % |
 |
CHINA | 3.6 % |
 |
DENMARK | 3.4 % |
 |
GERMANY | 3.4 % |
 |
NETHERLANDS | 3.3 % |
 |
IRELAND | 3.2 % |
Historical Performance
Standardized Performance (as of 07/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 18.7% | 49.2% | 21.0% | 16.3% | 7.9% | 9.3% | 13.3% | 13.3% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.1% | 0.2% | 0.2% |
| Total Returns | 18.7% | 49.2% | 21.0% | 16.3% | 8.1% | 9.5% | 13.4% | 13.4% | Ann. Volatility | 22.7% | 21.4% | 22.6% | 20.9% | 22.1% | 23.8% | 25.5% | 25.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.78 | 22% |
| MSCI EAFE | 0.71 | 27% |
| MSCI Emg Mkts | 0.33 | 14% |
Liquidity Measures
| Avg. volume (000) | 90 |
| ADV traded (mns) | $23 |
| Turnover | 0.8% |
| Avg. Bid/Ask (% of price) | 0.14% |
Technical Indicators
| 30d moving avg. (EMA) | $244.14 |
| Relative strength (RSI) | 57 |
| MACD/Signal | 3.05/4.12 |
| Bollinger Bands (Upper/Lower) | $256.58/$242.57 |
| Short interest (% of AUM) | 0.7% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FBT |
Expenses vs. FBT |
ALTAR Score™ vs. FBT |
|---|---|---|---|---|
| PBE | Invesco Biotechnology & Genome ETF | 51.8% | +2 bp | +1.2% |
| BBH | VanEck Biotech ETF | 45.6% | -21 bp | +2.5% |
| IBB | iShares Biotechnology ETF | 43.7% | -11 bp | -2.1% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 34.4% | -37 bp | -1.3% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 31.0% | +4 bp | +5.2% |
| BMED | Future Health ETF | 29.0% | +29 bp | -0.8% |
| BBP | Virtus LifeSci Biotech Products ETF | 27.0% | +23 bp | -5.1% |
| GNOM | Global X Genomics & Biotechnology ETF | 26.5% | -6 bp | -4.1% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 25.3% | -21 bp | -5.0% |
| FXH | First Trust Health Care AlphaDEX Fund | 23.2% | +6 bp | +3.3% |
Risk and Returns: FBT vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 8/9/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
1.6%
ALTAR SCORE™
3rd
PERCENTILE
AVOID
ETFRC RATING
There are 1,402 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. FBT's ALTAR Score™ is approximately -1.8 standard
deviations above the category average. This places FBT in the 3rd percentile
among funds in the category.
Sell-Side Consensus
$268.34
PRICE TARGET
+4.8%
UPSIDE